Innate Pharma S.A. (NASDAQ: IPHA)
$2.10
-0.0550 ( -2.56% ) 0.6K
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Market Data
Open
$2.10
Previous close
$2.15
Volume
0.6K
Market cap
$179.71M
Day range
$2.12 - $2.23
52 week range
$1.81 - $3.29
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 2 | Apr 15, 2024 |
6-k | Quarterly Reports | 2 | Apr 10, 2024 |
20-f | Annual reports | 250 | Apr 04, 2024 |
6-k | Quarterly Reports | 2 | Mar 21, 2024 |
6-k | Quarterly Reports | 2 | Mar 21, 2024 |
6-k | Quarterly Reports | 2 | Mar 19, 2024 |
6-k | Quarterly Reports | 2 | Mar 14, 2024 |
6-k | Quarterly Reports | 2 | Mar 06, 2024 |
6-k | Quarterly Reports | 2 | Mar 06, 2024 |
6-k | Quarterly Reports | 2 | Feb 21, 2024 |